Our Vision
We aim at changing the way drug development research is done today by providing in-vitro models that reproduce the in-vivo environment in an unprecedented way. These in-vitro models, called organ-on-chips, will make it possible to better predict drugs’ responses in humans than standard in-vitro and in-vivo models and as a consequence to importantly reduce animal testing.
Our Mission
AlveoliX provides in-vitro solutions based on proprietary and unique organ-on-chip technologies aimed at improving preclinical decision-making and thus reducing drug development costs.
Company Details
- Employees
- 14
- Founded
- 2019
- Address
- Freiburgstrasse 3, Bern,3010,switzerland
- in****@****lix.com
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- alveolix.com
- Keywords
- Research, Innovation, Technology, In-vitro, 3D Cell Culture, Organ-on-Chip, Respiratory diseases, Drug Development, Drug Discovery, Preclinical Services, Safety, Efficacy, Toxicity, Inhalation.
- HQ
- Bern
Alveolix Questions
Alveolix's website is alveolix.com
Alveolix's LinkedIn profile is https://ch.linkedin.com/company/alveolix
Alveolix has
14 employees.
View email and phone details for 14
employees at Alveolix.
Alveolix's industry is
Biotechnology Research
Alveolix's top competitors are
Mimetas,
Insphero,
Ncardia,
Tissuse Gmbh,
Bi/ond,
Cherry Biotech,
Emulate, Inc.,
Hub Organoids,
4dcell,
Netri.
Alveolix's support email address is info@alveolix.com
Alveolix's categories are Biotechnology Research
Alveolix's founding year is 2019
